Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03373279
Other study ID # 016-114
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 1, 2017
Est. completion date December 30, 2023

Study information

Verified date January 2023
Source Baylor Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with marginal physiologic reserve, severe frailty, and/or malnutrition may be regarded as unsuitable candidates for advanced cardiac replacement therapies. However, little data exist on precisely which measures are predictive of subsequent adverse events. Assessment of nutritional status and frailty is still largely predicated on crude and obsolete parameters, such as baseline serum albumin level or body mass index (BMI). In this prospective cohort study the investigators will evaluate the use of bio-electrical impedance spectroscopy (BIS) as a measure of body composition and assess the associations with surgical outcomes.


Description:

This is a prospective cohort study, with study visits at Enrollment and subsequently at ≤10 days , 1 month (+/- 7 days), 3 months (+/- 7 days) , 6 months (+/- 14 days) , and 12 months (+/- 14 days) after heart transplant surgery. BIS measurements will be performed on patients both in the pretransplant and post-transplant periods except when contraindicated in the pretransplant setting concerning patients with advanced heart failure. Because the use of BIS is contraindicated in the setting of permanent pacemaker and/or internal cardiac defibrillator (ICD) devices, BIS assessment cannot be performed in the pretransplant setting for patients with advanced heart failure as the majority of these patients already have these devices in place. However, at the time of cardiac transplantation, these devices will be removed from those patients with advanced heart failure and the BIS measurements will then be performed shortly after transplantation, and then serially during the post-transplant period at various time intervals for one year in order to track changes in body composition. These measurements will be compared to traditional measurements performed at the time of preoperative evaluation by the nutritional and dietitian support team.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 69
Est. completion date December 30, 2023
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Listed for a native heart transplant at BUMC - At least 18 years of age Exclusion Criteria: - Women during pregnancy - Patient currently has a ventricular assist device

Study Design


Related Conditions & MeSH terms

  • Heart Transplant Failure and Rejection

Locations

Country Name City State
United States Baylor University Medical Center Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
Baylor Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary BIS Parameters Predictive of Adverse Outcomes BIS-derived elements such as FM and FFM will be compared with standard preoperative variables for correlation of malnutrition assessment and predictability of adverse clinical events such as mortality, primary graft dysfunction, rejection, acute kidney injury, prolonged hospital stay, and hospital readmission. Several measures of nutrition status will be measured including SGA, BMI, tricep skinfolds, midarm muscle circumference, and FFM via BIS. The methods will be compared to determine agreement among the methods in determining malnutrition. In addition, nutrition status measures will be repeated at specified times over the first year following heart transplantation to describe the changes in body composition after transplantation. These changes occur gradually and thus the initial postoperative measurement will be closely representative of the patient's initial (pre-transplant) baseline status. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT03102125 - Allograft Dysfunction in Heart Transplant Phase 4
Active, not recruiting NCT04380311 - Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant N/A
Completed NCT02109575 - Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
Completed NCT04610320 - Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation Phase 1
Active, not recruiting NCT03386539 - Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Phase 3
Withdrawn NCT05081739 - Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation N/A
Recruiting NCT03499197 - Heart TIMING - Heart Transplantation IMagING
Recruiting NCT03538509 - Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
Recruiting NCT03050892 - Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation N/A
Recruiting NCT05994274 - A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
Active, not recruiting NCT03575910 - HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
Withdrawn NCT04088903 - Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation Phase 1